Journal
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 35, Issue 3, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2021.101666
Keywords
Systemic sclerosis; Scleroderma; Gastrointestinal; Management
Categories
Funding
- NIH/NIAMS [K23 AR071473]
- Scleroderma Research Foundation
- Jerome L. Greene Foundation
Ask authors/readers for more resources
Systemic sclerosis often affects the gastrointestinal tract, leading to impaired function and significant morbidity. This article consolidates current guidelines and proposes a symptom-based framework for diagnosis and management, while also identifying areas in need of further research.
The gastrointestinal (GI) tract is the most commonly affected internal organ system in systemic sclerosis (SSc). SSc may lead to impaired function in any region of the GI tract, from the esophagus to the anorectum, which causes significant morbidity as well as mortality in patient subsets. Given the low prevalence of SSc in the community, many rheumatologists may not have a systematic framework for diagnosing or treating the GI complaints in this disease. These practice recommendations aim to summarize and consolidate the current guidelines from the fields of gastroenterology and rheumatology and establish a symptom-based framework for diagnosis and management based on available evidence in the literature. Subject areas that are in need of additional research are also identified. (C) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available